2-cyano-N-[2-(2,4-dichlorophenyl)ethyl]acetamide | 1016772-96-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-cyano-N-[2-(2,4-dichlorophenyl)ethyl]acetamide
• CAS: 1016772-96-5
• 化学式: C₁₁H₁₀Cl₂N₂O
• mdl: MFCD09934501
• 分子量: 257.119
• InChiKey: YRJRLABEQWEBKO-UHFFFAOYSA-N

物化性质

• 沸点：
  483.3±45.0 °C(predicted)
• 密度：
  1.318±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-cyano-N-[2-(2,4-dichlorophenyl)ethyl]acetamide 在 potassium carbonate 、 三乙胺 、 potassium iodide 作用下， 以 乙醇 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  开发喹唑啉酮和香草醛丙烯酰胺杂化物作为抗阿尔茨海默氏病的多靶点定向配体，及其与乙酰胆碱酯酶结合的机制见解

  摘要：

  鉴于多靶点定向配体（MTDL）方法治疗阿尔茨海默病（AD），一系列新型喹唑啉酮和香草醛氰基乙酰胺基丙烯酰胺衍生物（9a-z）被开发出来。

  DOI：

  10.1080/07391102.2023.2203255
• 作为产物：
  描述：

  2,4-二氯苯酚呋喃 、 氰乙酸乙酯 以 乙醇 为溶剂， 生成 2-cyano-N-[2-(2,4-dichlorophenyl)ethyl]acetamide
  参考文献：
  名称：

  开发喹唑啉酮和香草醛丙烯酰胺杂化物作为抗阿尔茨海默氏病的多靶点定向配体，及其与乙酰胆碱酯酶结合的机制见解

  摘要：

  鉴于多靶点定向配体（MTDL）方法治疗阿尔茨海默病（AD），一系列新型喹唑啉酮和香草醛氰基乙酰胺基丙烯酰胺衍生物（9a-z）被开发出来。

  DOI：

  10.1080/07391102.2023.2203255

文献信息

• Discovery of chromenes as inhibitors of macrophage migration inhibitory factor
  作者：Tjie Kok、Hannah Wapenaar、Kan Wang、Constantinos G. Neochoritis、Tryfon Zarganes-Tzitzikas、Giordano Proietti、Nikolaos Eleftheriadis、Katarzyna Kurpiewska、Justyna Kalinowska-Tłuścik、Robbert H. Cool、Gerrit J. Poelarends、Alexander Dömling、Frank J. Dekker

  DOI：10.1016/j.bmc.2017.12.032

  日期：2018.3

  Macrophage migration inhibitory factor (MIF) is an essential signaling cytokine with a key role in the immune system. Binding of MIF to its molecular targets such as, among others, the cluster of differentiation 74 (CD74) receptor plays a key role in inflammatory diseases and cancer. Therefore, the identification of MIF binding compounds gained importance in drug discovery. In this study, we aim to discover novel MIF binding compounds by screening of a focused compound collection for inhibition of its tautomerase enzyme activity. Inspired by the known chromen-4-one inhibitor Orita-13, a focused collection of compounds with a chromene scaffold was screened for MIF binding. The library was synthesized using versatile cyanoacetamide chemistry to provide diversely substituted chromenes. The screening provided inhibitors with IC50's in the low micromolar range. Kinetic evaluation suggested that the inhibitors were reversible and did not bind in the binding pocket of the substrate. Thus, we discovered novel inhibitors of the MIF tautomerase activity, which may ultimately support the development of novel therapeutic agents against diseases in which MIF is involved. (C) 2017 Elsevier Ltd. All rights reserved.
• One-Pot Synthesis of 2-Amino-indole-3-carboxamide and Analogous
  作者：Kan Wang、Eberhardt Herdtweck、Alexander Dömling

  DOI：10.1021/co100040z

  日期：2011.3.14

  An efficient one-pot, two-step solution-phase synthetic method was developed to synthesize twenty-three 2-amino-indole-3-carboxamides (3) from 2-halonitrobenzene (1) or heterocyclic analogous and cyanoacetamides (2). In this sequence, first, intermediate 2cyano-2-(2-nitrophenyl)acetamide (4) was generated under basic condition via S(NAr) reaction; after direct addition of hydrochloric acid solution, FeCl(3), and Zn powder, indole 3 was generated via reduction/cyclization process.
• Development of quinazolinone and vanillin acrylamide hybrids as multi-target directed ligands against Alzheimer’s disease and mechanistic insights into their binding with acetylcholinesterase
  作者：Kandrakonda Yelamanda Rao、Shaik Jeelan Basha、Kallubai Monika、Navya Naidu Gajula、Irla Sivakumar、Sandeep Kumar、Ramakrishna Vadde、Bindu Madhava Reddy Aramati、Rajagopal Subramanyam、Amooru Gangaiah Damu

  DOI：10.1080/07391102.2023.2203255

  日期：2023.12.21

  In view of Multi-Target Directed Ligand (MTDL) approach in treating Alzheimer’s Disease (AD), a series of novel quinazolinone and vanillin cyanoacetamide based acrylamide derivatives (9a-z) were de...

  鉴于多靶点定向配体（MTDL）方法治疗阿尔茨海默病（AD），一系列新型喹唑啉酮和香草醛氰基乙酰胺基丙烯酰胺衍生物（9a-z）被开发出来。